Colin Movsowitz

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias

BACKGROUND Patients who survive life-threatening ventricular arrhythmias are at risk for recurrent arrhythmias. They can be treated with either an implantable cardioverter-defibrillator or antiarrhythmic drugs, but the relative efficacy of these two treatment strategies is unknown. METHODS To address this issue, we conducted a randomized comparison of these two treatment strategies in patients who had been resuscitated from near-fatal ventricular fibrillation or who had undergone cardioversion from sustained ventricular tachycardia. Patients with ventricular tachycardia also had either syncope or other serious cardiac symptoms, along with a left ventricular ejection fraction of 0.40 or less. One group of patients was treated with implantation of a cardioverter-defibrillator; the other received class III antiarrhythmic drugs, primarily amiodarone at empirically determined doses. Fifty-six clinical centers screened all patients who presented with ventricular tachycardia or ventricular fibrillation during a period of nearly four years. Of 1016 patients (45 percent of whom had ventricular fibrillation, and 55 percent ventricular tachycardia), 507 were randomly assigned to treatment with implantable cardioverter-defibrillators and 509 to antiarrhythmic-drug therapy. The primary end point was overall mortality. RESULTS Follow-up was complete for 1013 patients (99.7 percent). Overall survival was greater with the implantable defibrillator, with unadjusted estimates of 89.3 percent, as compared with 82.3 percent in the antiarrhythmic-drug group at one year, 81.6 percent versus 74.7 percent at two years, and 75.4 percent versus 64.1 percent at three years (P<0.02). The corresponding reductions in mortality (with 95 percent confidence limits) with the implantable defibrillator were 39+/-20 percent, 27+/-21 percent, and 31+/-21 percent CONCLUSIONS Among survivors of ventricular fibrillation or sustained ventricular tachycardia causing severe symptoms, the implantable cardioverter-defibrillator is superior to antiarrhythmic drugs for increasing overall survival.

Ambulatory External Electrocardiographic Monitoring: Focus on Atrial Fibrillation

There has been progressive development in ambulatory external electrocardiogram (AECG) monitoring technology. AECG monitors initially consisted of 24- to 48-h Holter monitors and patient-activated event and loop recorders. More recently, several ambulatory cardiovascular telemetry monitors and a patch-type 7- to 14-day Holter monitor have been introduced. These monitoring systems are reviewed along with their utility and limitations, with particular emphasis on their role in the diagnosis and evaluation of patients with atrial fibrillation (AF). AECG monitoring is necessary when asymptomatic AF is suspected (as in patients presenting with cryptogenic stroke) or when an ECG diagnosis of unexplained arrhythmic symptoms is warranted. In addition, AECG plays an important role in patients with known AF to guide ventricular rate control and anticoagulation therapy, and assess the efficacy of antiarrhythmic drug therapy and/or ablation procedures. Finally, we outline areas of uncertainty and provide recommendations for use of available AECG monitors in clinical practice.

Efficacy and safety of catheter ablation in octogenarians.

OBJECTIVES To determine whether catheter ablation is safe and effective in patients over the age of 80. BACKGROUND There is a tendency to withhold invasive therapy in the elderly until it has been proven safe and effective. METHODS Over a two-year period from February 1, 1996 to February 1, 1998, 695 consecutive patients underwent 744 catheter ablation procedures of supraventricular and ventricular arrhythmias. These patients were divided into three groups based on age: > or =80 years, 60 to 79 years and <60 years. Acute ablation success, using standard criteria and complication rates for these three groups were determined. RESULTS There were 37 patients > or =80 years, 275 patients 60 to 79 years and 383 patients <60 years old. The overall acute ablation success rate for the entire group was 95% with no difference in rates among the three groups (97%, > or =80 years; 94%, 60-79 years; 95%, <60 years). The percentage of patients undergoing His bundle ablation was greatest in the > or =80-year-old group (43% vs. 19% vs. 2%, p < 0.01), and the percentage of patients undergoing accessory pathway ablation was greatest in the <60-year-old patients (0% vs. 4% vs. 25%, p < 0.01). The overall complication rate for the entire group was 2.6%, and there was only one major/life-threatening complication. There was no difference in complication rates among the groups (0%, > or =80 years; 2.2%, 60 to 79 years; 3.1%, <60 years). Based on the sample size, the 95% confidence interval is 0% to 7.8% for an adverse event in the octogenarian. CONCLUSIONS Catheter ablative therapy for the arrhythmias attempted in the very elderly appears to be effective with low risk. Ablation results appear to be comparable with those noted in younger patients.

The results of atrial flutter ablation in patients with and without a history of atrial fibrillation

To determine the impact of atrial flutter radiofrequency catheter ablation on recurrence of atrial flutter and atrial fibrillation, 32 patients with atrial flutter (18 with a history of atrial fibrillation) were followed for a mean of 8.6 months; atrial flutter has not recurred after 1 (26 patients) or 2 (5 patients) successful ablation procedures. Atrial flutter did not appear proarrhythmic for atrial fibrillation, with only 1 of 15 patients without a history of atrial fibrillation developing the arrythmia in the absence of an alcohol binge or cocaine use.

Remote patient management using implantable devices.

Remote patient management utilizing the Internet is a milestone in the management of patients with an implantable cardiac device. Pacemakers and implantable cardioverter–defibrillators (ICDs) store diagnostic information about device and lead integrity, the occurrence of atrial and ventricular arrhythmias, and parameters that may reflect on a patient’s heart failure status. Previously, these data could only be retrieved with a programmer at an in-person office visit. The introduction of remote follow-up and monitoring has changed the paradigm for the management of patients with implanted devices. Remote follow-up has been shown to be superior to traditional transtelephonic monitoring for the detection of clinically actionable events in pacemaker patients. Remote monitoring using ICDs with wireless technology has been demonstrated to result in detection of lead malfunction and atrial and ventricular arrhythmias while reducing the need for in-office evaluations without compromising patient safety. Studies are underway to evaluate the clinical utility of identification of atrial high-rate episodes and to identify patients at risk for exacerbation of heart failure. Remote monitoring technology has yet to be universally adopted by patients or physicians. Impediments to the implementation of remote monitoring including issues related to work flow and data management are explored.

Effect of Different Location of Atrial Lead Position on Nearfield and Farfield Electrograms in Dual Chamber Pacemaker-Defibrillators

The normal functioning of dual chamber pacemaker-cardioverter defibrillator (AV pacer/ICD) may be affected by oversensing of the farfield R wave (FFRW) by the atrial channel. This study aimed to investigate whether placement of the AV pacer/ICDs atrial lead at a lateral (LAT) wall location compared to a medial (MED) location i.e. the appendage of the right atrium, would reduce the amplitude of FFRWs but not the nearfield atrial electrograms (AEGMs) during sinus rhythm (SR) and ventricular fibrillation (VF). In 17 patients, real time electrograms were recorded during SR and induced VF through the atrial lead initially at the MED and subsequently at the LAT location. In 10 patients the electrograms in SR were also recorded on a computerized data acquisition and recording system at different band-pass filter settings. Although FFRWs were recorded both at MED and LAT locations, they were much smaller, 3.5±4.1[emsp4 ]mm during SR and 1.7±2.2[emsp4 ]mm during VF at the LAT location. At 30–500[emsp4 ]Hz band-pass filter, lower amplitudes of FFRWs 0.14±0.09[emsp4 ]mV were recorded at the LAT location. The V/A ratios of the amplitudes of FFRWs and AEGMs were smaller at the LAT location during SR and VF. The nearfield AEGMs were of similar amplitudes at the MED and LAT locations. These data indicate that lower amplitudes of FFRWs are recorded by placement of the atrial lead at the lateral wall of the right atrium. Oversensing of FFRWs may be prevented to improve functioning of the AV pacer-ICD.

The Modern EP Practice: EHR and Remote Monitoring

Cardiac implantable electronic devices (CIEDs) store clinically valuable, time-sensitive information regarding system integrity, arrhythmias, and heart failure parameters. Remote monitoring has impacted clinical practice by reducing scheduled office visits, providing protocols for device recalls and advisories, and facilitating the management of unscheduled encounters. The successful implementation of remote monitoring into clinical practice requires a new work flow and additional staff; the use of the electronic medical record to manage the data emanating from CIEDs poses an additional challenge. Solutions to these issues are discussed, and projections are made regarding the management of CIEDs in a modern electrophysiology practice.

Left ventricular diastolic response to exercise in valvular aortic stenosis

Exercise produces profound alterations in symptoms and hemodynamics in patients with valvular aortic stenosis (AS). Prior studies have demonstrated marked increases in late left ventricular (LV) diastolic filling pressure with exercise. Little information is available on the exercise response of indexes of early LV diastolic performance. Catheter-tip manometer recordings in 11 patients with AS and 5 age-matched controls were obtained at rest and with supine bicycle exercise at the time of cardiac catheterization. Pressure-derived indexes of LV diastolic performance, isovolumic relaxation rate, and diastolic interval data were examined. At rest, early (patients 22 +/- 6 mm Hg, controls 12 +/- 3 mm Hg; p < 0.01), minimal (patients 9 +/- 4 mm Hg, controls 4 +/- 1 mm Hg; p < 0.01), and late (patients 28 +/- 10 mm Hg, controls 13 +/- 3 mm Hg; p < 0.002) LV diastolic pressures were elevated in patients with AS. The time to onset of isovolumic relaxation (patients 422 +/- 31 ms, controls 363 +/- 40 ms; p < 0.01) and minimal LV diastolic pressure (patients 608 +/- 57 ms, controls 448 +/- 52 ms; p < 0.002) at rest were prolonged in patients with AS. With exercise, early (patients 45 +/- 14 mm Hg, controls 15 +/- 3 mm Hg; p < 0.002), minimal (patients 15 +/- 6 mm Hg, controls 2 +/- 1 mm Hg; p < 0.01), and late (patients 38 +/- 10 mm Hg, controls 18 +/- 5 mm Hg; p < 0.002) LV diastolic pressures were elevated, and the time to minimal LV diastolic pressure (patients 528 +/- 26 ms; controls 393 +/- 56 ms) and peak first derivative of LV pressure decline (-LV dP/dt) patients 395 +/- 41 ms, controls 326 +/- 59 ms) were prolonged in AS. Furthermore, patients with AS failed to comparably increase the rate of LV pressure decay and isovolumic relaxation with exercise. The LV diastolic response to exercise in patients with AS is distinguished from the control response by suboptimal and prolonged relaxation and a diminished rate of LV pressure decay. These abnormal responses in early diastolic function coupled with the known abnormal chamber distensibility in AS contribute to significant elevations in early, mid-, and late diastolic pressures with exercise.

705-4 Idiopathic Right Ventricular Outflow Tract Tachycardia: Narrowing the Anatomic Location for Successful Ablation

Pace mapping used to locate the site for ablation of idiopathic right ventricular outflow tract (RVOT) ventricular tachycardia remains difficult and time-consuming. A method to facilitate pace mapping and the most common site of ablation of this tachycardia are reported. In 18 consecutive patients with RVOT ventricular tachycardia, electrocardiographic criteria based on the QRS orientation in lead 1 and the R wave progression in the precordial leads were used to find pace maps matching the arrhythmia. Identical pace maps were obtained on the septum of the RVOT in 16 patients and resulted in successful ablations. These sites were concentrated in the anterior superior aspect of the RVOT determined by fluoroscopic imaging. In the remaining two cases identical pace maps could not be found in this area. The results of this study narrow the anatomic location for radiofrequency ablation of idiopathic RVOT ventricular tachycardia. This is the first description of an electrocardiography-guided approach to finding an identical pace map in the RVOT.